Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics (STARRING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03288012
Recruitment Status : Unknown
Verified August 2018 by Sanquin Research & Blood Bank Divisions.
Recruitment status was:  Recruiting
First Posted : September 19, 2017
Last Update Posted : July 19, 2019
Sponsor:
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Radboud University Medical Center
HagaZiekenhuis
Erasmus Medical Center
Information provided by (Responsible Party):
Sanquin Research & Blood Bank Divisions

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : December 31, 2021